Compare GSK plc (GSK) vs JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs JPMorgan Nasdaq Equity Premium Income ETF — how do they compare? GSK plc trades at $50.37 (market cap $102.60B), while JPMorgan Nasdaq Equity Premium Income ETF trades at $60.06. The key difference: GSK plc pays a 3.57% dividend while JPMorgan Nasdaq Equity Premium Income ETF pays none, and JPMorgan Nasdaq Equity Premium Income ETF is trading nearer its 52-week high, GSK plc nearer its low. Which is the better fit depends on your goals.
| GSK | JEPQ | |
|---|---|---|
Market Cap | $102.60B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $61.18 | $61.46 |
52-Week Low | $38.22 | $53.77 |
Enterprise Value | $123.04B | — |
Dividend Yield | 3.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
JEPQ trades at $60.00, up 0.54% with a bullish technical signal from moving averages. The ETF's covered-call strategy generates monthly income, with recent dividends of $0.70, $0.64, and $0.56. News highlights focus on retirement income strategies and tax implications of distributions. Institutional interest remains strong, with Bank of America increasing its stake by 8.9% in Q1 2026.
Outlook remains positive for income-focused investors, though the RSI suggests potential overbought conditions. Key risks include tax treatment of distributions and market volatility affecting the options strategy. The fund's $39 billion AUM and active management support its popularity for yield generation in retirement portfolios.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About JPMorgan Nasdaq Equity Premium Income ETF
JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.
Read more on JEPQ →
